Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …

Objectives Several studies have evaluated the economic evaluation of a group of
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …

Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

Objective: Results of randomized clinical trials (RCT) demonstrate that novel oral
anticoagulants (NOAC) are effective therapies for reducing the risk of stroke in non-valvular …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …

Background Previous investigations into the cost effectiveness of direct oral anticoagulants
only considered individual stroke risk but not bleed risk even though bleeding is an …

Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as preferred options for stroke prevention in patients with atrial fibrillation …